---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107747"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:46:36.639985+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma reports Q3 net loss of $3.9M, raises up to $105.3M in private placement

## Summary
- Net loss of $3.9M for Q3 2025 ($11.5M YTD) vs $2.3M and $6.7M in prior-year periods; R&D spend increased to $2.3M for Q3.
- Cash, equivalents, and marketable securities totaled $5.4M as of Sept 30; Oct 2025 added $16.6M upfront from private placement, extending runway into 2027.
- Private placement financing closed Oct 2025 with potential gross proceeds up to $105.3M including warrants exercise.
- Sally Lawlor appointed CFO; FDA granted Orphan Drug Designation for QRX003 for Netherton Syndrome; pivotal studies to start Q4 2025.
- NETHERTON NOW campaign surpassed 1.5M video views since Feb 2025; positive Peeling Skin Syndrome data released.

## SEC filing metadata
- accession: 0001104659-25-107747
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925107747/0001104659-25-107747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925107747/tm2530187d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107747
- JSON: https://secwatch.observer/filing/0001104659-25-107747.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.